Roberts C R, Mitra R, Hyams K, Brodine S K, Lal R B
Department of Diagnostic Retrovirology, Walter Reed Army Institute of Research, Washington, D.C.
J Med Virol. 1992 Apr;36(4):298-302. doi: 10.1002/jmv.1890360412.
Synthetic peptide-based serologic assays (Select-HTLV and SynthEIA) that distinguish the closely related human T-cell lymphotropic virus types I (HTLV-I) and II (HTLV-II) were tested blindly for their ability to correctly identify infection caused by either virus type. Of 57 HTLV-I and 38 HTLV-II specimens from individuals whose infections were confirmed by polymerase chain reaction, the Select-HTLV assay categorized 56 (98%) as HTLV-I, 36 (95%) as HTLV-II, and 3 (3%) as nontypeable. Similarly, the SynthEIA assay categorized 54 (95%) as HTLV-I, 29 (76%) as HTLV-II, and 12 (13%) as nontypeable. More importantly, no specimen was wrongly classified by either assay (100% specificity). Further, analysis of serial specimens from six patients also demonstrated concordant results with the PCR findings. Our results suggest that serotyping of HTLV infections can be achieved reliably by these peptide assays, thus the need for technically complex PCR-based HTLV typing, while not eliminated, can be greatly reduced.
用于区分密切相关的人类T细胞嗜淋巴细胞病毒I型（HTLV-I）和II型（HTLV-II）的基于合成肽的血清学检测方法（Select-HTLV和SynthEIA），对其正确识别由任一病毒类型引起的感染的能力进行了盲法检测。在57份经聚合酶链反应确认感染的HTLV-I标本和38份经聚合酶链反应确认感染的HTLV-II标本中，Select-HTLV检测将56份（98%）归类为HTLV-I，36份（95%）归类为HTLV-II，3份（3%）归类为无法分型。同样，SynthEIA检测将54份（95%）归类为HTLV-I，29份（76%）归类为HTLV-II，12份（13%）归类为无法分型。更重要的是，两种检测方法均未出现错误分类的标本（特异性为100%）。此外，对6名患者的系列标本分析也显示与聚合酶链反应结果一致。我们的结果表明，通过这些肽检测方法能够可靠地实现HTLV感染的血清学分型，因此，虽然基于聚合酶链反应的技术复杂的HTLV分型需求并未消除，但可以大大减少。
